Protein / target

Toll-like receptor 1

Encoded byTLR1Q15399Homo sapiensSwiss-Prot

UniProt: Q15399 Ensembl: ENSG00000174125 HGNC: HGNC:11847 NCBI Gene: 7096

Small-molecule tractable

Druggability

Structure with Ligand

Research papers

Protein at a glance

Biological role

Transmembrane signaling receptor

Strongest disease association

Asthma

Via encoding gene TLR1 · Genetic evidence · score 0.95

Research activity

Emerging research

4 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Participates in the innate immune response to microbial agents.

View complete UniProt function annotation

Participates in the innate immune response to microbial agents. Specifically recognizes diacylated and triacylated lipopeptides. Cooperates with TLR2 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:21078852). Forms the activation cluster TLR2:TLR1:CD14 in response to triacylated lipopeptides, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response

Subcellular location

Cell membraneCytoplasmic vesicle, phagosome membraneMembrane raftGolgi apparatus

Domains and Gene Ontology detail (28)

Domains & features

LRRCTTIR

Gene Ontology

CGolgi apparatus
Cmembrane
Cmembrane raft
Cphagocytic vesicle membrane
Cplasma membrane
Cplasma membrane raft
CToll-like receptor 1-Toll-like receptor 2 protein complex
Fidentical protein binding
Flipopeptide binding
Fsignaling receptor activity
FToll-like receptor 2 binding
Ftransmembrane signaling receptor activity

786 aa · 90 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProtImmune signallingUniProt · GO

View supporting evidence

Lipid & lipoprotein metabolism

·Participates in the innate immune response to microbial agents. Specifically recognizes…

Immune signalling

·Participates in the innate immune response to microbial agents. Specifically recognizes…
·immune response
·inflammatory response
·innate immune response

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TLR1

Gene-level evidence surfaced through the gene TLR1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Asthma

0.95Well supported

Genetic evidence dominant · Open Targets 0.60

Rhinitis, Allergic

0.87Well supported

Genetic evidence dominant · Open Targets 0.53

Hypersensitivity

0.86Well supported

Genetic evidence dominant · Open Targets 0.53

Childhood onset asthma

0.82Well supported

Genetic evidence dominant · Open Targets 0.50

Respiratory Tract Diseases

0.80Well supported

Genetic evidence dominant · Open Targets 0.49

View evidence synthesis (5)

AsthmaWell supported

0.95

agreement 0.81–1.00

Genetic90%Literature10%

Open Targets aggregate 0.60 · 2 independent evidence families

Rhinitis, AllergicWell supported

0.87

agreement 0.73–1.00

Genetic98%Literature2%

Open Targets aggregate 0.53 · 2 independent evidence families

HypersensitivityWell supported

0.86

agreement 0.72–1.00

Genetic96%Literature4%

Open Targets aggregate 0.53 · 2 independent evidence families

Childhood onset asthmaWell supported

0.82

agreement 0.68–0.96

Genetic100%Literature0%

Open Targets aggregate 0.50 · 2 independent evidence families

Respiratory Tract DiseasesWell supported

0.80

agreement 0.66–0.94

Genetic99%Literature1%

Open Targets aggregate 0.49 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Asthma0.60

Rhinitis, Allergic0.53

Hypersensitivity0.53

Childhood onset asthma0.50

Respiratory Tract Diseases0.49

Rosacea0.45

Seasonal allergic rhinitis0.44

Arthritis, Rheumatoid0.43

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (9)

SM · Structure with LigandSM · High-Quality LigandSM · Med-Quality PocketAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.